Tedisamil: A new novel antiarrhythmic

Expert Opinion on Investigational Drugs

Volumn 13, Issue 2, 2004, Pages 151-160

  Freestone, Bethan ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Antiarrhythmic; Cardiovascular; Potassium channel blocker; Tedisamil

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; AZIMILIDE; BIMAKALIM; BRETYLIUM; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; ENCAINIDE; ESMOLOL; FLECAINIDE; GALLOPAMIL; IBUTILIDE; LIDOCAINE; METOPROLOL; MEXILETINE; NEW DRUG; PIBOSEROD; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; TEDISAMIL; UNINDEXED DRUG; VERAPAMIL;

ANGINA PECTORIS; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ECG ABNORMALITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE POTENTIAL; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; INOTROPISM; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LUNG TOXICITY; NEUROTOXICITY; NONHUMAN; PHOTOSENSITIVITY; QT PROLONGATION; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; THYROID DISEASE; TORSADE DES POINTES;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYCLOPROPANES; DOGS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; EXPERT TESTIMONY; HUMANS; INJECTIONS, INTRAVENOUS; RATS;

EID: 1242307392     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.2.151     Document Type: Article

References (48)

1. KANNEL WB, WOLF PA, BENJAMIN EJ et al.: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. (1998) 82:2N-9N.
2. ANDERSON J: Acute treatment of atrial fibrillation and flutter. J. Am. Coll. Cardiol. (1996) 17:17-21.
3. COPLEN SE, ANTMAN EM, BERLIN JA et al.: Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion. A meta-analysis of randomised control trials. Circulation (1990) 82:1106-1116.
4. THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL INVESTIGATORS: Preliminary report: effect of ecainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. New Engl. J. Med. (1989) 321:406-412.
5. RAWLES JM, METCALF MJ, JENNINGS K: Time of occurrence, duration and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br. Heart J. (1990) 63:225-227.
6. MOSS AJ, DAVIS HT, CONARD DL et al.: Digitalis associated mortality after myocardial infarction. Circulation (1981); 64:1150-1156.
7. HILLEMAN DE, SPINLER A: Conversion of recent onset of atrial fibrillation with amiodarone: a meta-analysis of randomised control trials. Pharmacotherapy (2002) 22:66-74.
8. JUUL-MOLLER S, EDVARSSON N, REHGVIST-AHLBERG N et al.: Sotalol versus quinidine for maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation. Circulation (1990) 82:1932-1939.
9. LEE SH, CHEN SA, TAI DT: Comparison of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am. J. Cardiol. (1997) 79:905-908.
10. REIMOLD SC, CANTILLON CO, FRIEDMAN PL et al.: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am. J. Cardiol. (1993) 71:558-563.
11. SINGH SN, ZABL RG, YELLEN LG et al.: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter. The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation (2000) 102:2385-2390.
12. STAMBLER BS, WOOD MA, ELLENBOGEN KA: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation (1996) 94:1613-1621.
13. + current in rat ventricular myocytes. Am. J. Physiol. (1989) 257:H1746-H1749.
14. BERGER F, BORCHARD U, HAFNER D et al: Different inhibition patterns of tedisamil for fast and slowly inactivation transient outward current in rat ventricular myocytes. Naunyn-schiedeberg's Arch. Pharmacol. (1998) 357:291-298.
15. WETTWER E, HIMMEL HM, AMOS GJ et al: Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br. J Pharmacol. (1998) 125:659-666.
16. + currents in mammalian cardiac and glial cells. J. Pharmacol. Exp. Ther. (1990) 254:560-569.
17. WETTWER E, GERWER M, TAMKUN MM et al.: Native versus cloned Kv1.5 channel: effects of tedisamil on human cardiac delayed rectifier currents. ESC Barcelona (1999) (Abstract 329)
18. + channels in adult rat ventricular cells. J. Mol. Cell. Cardiol. (1992) 24:S40.
19. CHI L, PARK JL, FRIEDRICHS GS et al.: Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br. J. Pharmacol. (1996) 117:1261-1269.
20. FAIVRE JF, ROUANET S, BRIL A: Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031 and BRL-32872 on protein kinase-activated chloride current in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol. (1998) 31:551-557.
21. + current blocker. Br. J. Pharmacol. (1991) 102:13-18.
22. DORIAN P, NEWMAN D: Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements. Cardiovasc. Res. (1997) 33:485-494.
23. NEMETH M, VARRO A, VIRAG L et al.: Frequency-dependent cardiac electrophysiologic effects of tedisamil: comparison with quinidine and sotalol. J. Cardiovasc. Pharmacol. Ther. (1997) 2:273-284.
24. NEMETH M, VIRAG L, HALA O et al.: The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers. Cardiovasc. Res. (1996) 31:246-248.
25. BARGHEER K, BODE F, KLEIN HU et al.: Prolongation on monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur. Heart J. (1994) 15:1409-1414.
26. WALLACE AA, STUPIENSKI RF 3rd, BASKIN EP et al.: Cardiac electrophysiologic and antiarrhythmic actions of tedisamil. J. Pharmacol. Exp. Ther. (1995) 273:168-175.
27. CHI L, PARK JL, FRIEDRICHS GS et al.: Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br. J. Pharmacol. (1996) 117:1261-1269.
28. DORIAN P, NEWMAN D: Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements. Cardiovasc. Res. (1997) 33:485-494.
29. GROHS JG, FISCHER G, RABERGER G: Cardiac and hemodynamic effects of the selective bradycardic agent KC 8857 during exercise-induced myocardial ischemia. Eur. J. Pharmacol. (1989) 161:53-60.
30. DUCHOSAL F, OPIE H: KC8857, a new compound with combined bradycardic and positive inotropic effects. J. Mol. Cell. Cardiol. (1987) 19:(Suppl. III) (Abstract 19).
31. FUCHS A, BUSCHMANN G, ZIEGLER D et al: Tedisamil: cardiac electrophysiologic and functional effects in guinea pigs. Naunyn-schiedeberg's Arch. Pharmacol. (1989) 340:R72.
32. DOGGRELL SA, NAND V: Effects of tedisamil on cardiovascular tissues isolated from normo and hypertensive rats. J. Cardiovasc. Pharmacol. (2001) 6:261-272.
33. TSUCHIHASHI K, CURTIS MJ: Influence of tedisamil on the initiation and maintenance of ventricular fibrillation: chemical defibrillation by Ito blockade? J. Cardiovasc. Pharmacol. (1991) 18:445-456.
34. FRIEDRICHS GS, ABREU JN, DRISCOLL EM et al.: Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation. J. Cardiovasc. Pharmacol. (1998) 31:56-66.
35. FISCHBACH PS, JOHNSTON PV, FRIEDRICHS GS et al.: Tedisamil in a chronic canine model of atrial flutter. J. Cardiovasc. Pharmacol. (1999) 34:212-218.
36. FISCHBACH PS, BARRETT TD, GOYAL R et al.: Conversion of atrial fibrillation by the experimental drug tedisamil in two canine models. J. Cardiovasc. Electrophysiol. (2001) 12:1138-1144.
37. MITROVIC V, OEHM E, THORMANN J et al.: Comparison of the potassium channel blocker tedisamil and the beta-adrenoceptor blocker esmolol and the calcium channel antagonist gallopamil in patients with coronary artery disease. Clin. Cardiol. (1998) 21:492-502.
38. DEMOLIS JL, MARTEL C, FUNCK-BRENTANO C et al.: Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. Br. J. Clin. Pharmacol. (1997) 44:403-409.
39. HAYES E, COURTICE ID, ABRAHAM S et al.: Acute toxicity of tedisamil, a new potassium channel blocking drug. Pharmacol. Toxicol. (1993) 73:257-261.
40. + channels and modulates action potentials in rat hippocampal neurons. Neurosci. Lett. (2002) 319:79-82.
41. + channel blocker tedisamil on 86Rb efflux induced by cromakalim, high potassium and noradrenaline and on mechanical tension in rabbit isolated vascular smooth muscle. Naunyn-schmiedeberg's Arch. Pharmacol.(1992) 345:238-243.
42. BRAY K, QUAST U: Differential inhibition by tedisamil (KC 8857) and glibenclamide of the responses to cromakalim and minoxidil sulphate in rat isolated aorta. Naunyn-schmiedeberg's Arch. Pharmacol. (1992) 345:244-250.
43. THORMANN J, MITROVIC V, RIEDEL H et al.: Tedisamil (KC 8857) is a new specific bradycardic drug: does it also influence myocardial contractility? Analysis by the conductance (volume) technique in coronary artery disease. Am. Heart J. (1993) 125:1233-1246.
44. HERMANN HP, OHLER A, JUST H et al: Cardiac and hemodynamic effects of the sinus node inhibitor tedisamil dihydrochloride in patients with congestiveheart failure due to dilated cardiomyopathy. J. Cardiovasc. Pharmacol. (1998) 32:969-972.
45. BARRETT TD, HENNAN JK, FISCHBACH PS et al.: Tedisamil and dofetilide induced torsades de pointes, rate and potassium depenence. Br. J. Pharmacol. (2001) 132:1493-500.
46. MITROVIC V, OEHM E, THORMANN J et al.: Potassium channel openers and blockers in coronary artery disease. Comparison to beta-blockers and calcium antagonists. Herz (2000) 25:130-142.
47. FOX W, HENDERSON JR, KASKI JC et al.: Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker. Heart (2000) 83:167-171.
48. KOWEY PR, DORIAN P, BECKMANN K et al.: Tedisamil for rapid conversion of recent onset atrial fibrillation and flutter to normal sinus rhythm. The North American Society of Pacing and Electrophysiology (NASPE), Washington, US (2003) (Abstract 417).